



Access to Kidney Cancer Medicines in the UK – June 2022

| Trade name <i>Manufacturer</i> | Generic name | How it works | Indication | Availability |
|--|--|--|--|---|
| First-line treatments | | | | |
| Kisplyx plus Keytruda <i>Eisai/MSD</i> | Lenvatinib in combination with pembrolizumab | Targeted therapy plus immunotherapy: VEGF tyrosine kinase inhibitor (TKI) plus anti-PD1 checkpoint inhibitor Infusion plus oral medication | First-line treatment for advanced RCC | Restricted access under a Patient Access Scheme (PAS) in Scotland. Not available on the NHS in England and Wales. |
| Cabometyx plus Opdivo <i>Ipsen/BMS</i> | Cabozantinib in combination with nivolumab | Targeted therapy plus immunotherapy: VEGF tyrosine kinase inhibitor (TKI) plus anti-PD1 checkpoint inhibitor Oral medication plus infusion | First-line treatment for advanced RCC | Restricted access under a Patient Access Scheme (PAS) in Scotland. Not available on the NHS in England and Wales |
| Bavencio plus Inlyta <i>Merck/Pfizer</i> | Avelumab in combination with axitinib | Immunotherapy plus targeted therapy: Anti-PD-L1 checkpoint inhibitor plus VEGF tyrosine kinase inhibitor (TKI) Infusion plus oral medication | First-line treatment for advanced/metastatic RCC | Available via the Cancer Drugs Fund (CDF) for patients in England and Wales. Available on the NHS in Scotland |
| Keytruda plus Inlyta <i>MSD/Pfizer</i> | Pembrolizumab in combination with axitinib | Immunotherapy plus targeted therapy: Anti-PD1 checkpoint inhibitor plus VEGF tyrosine kinase inhibitor (TKI) Infusion plus oral medication | First-line treatment for advanced RCC | Available on the NHS in Scotland under a Patient Access Scheme (PAS). Not available on the NHS in England and Wales |
| Opdivo plus Yervoy <i>BMS</i> | Nivolumab in combination with ipilimumab | Immunotherapy: Anti-PD1 checkpoint inhibitor plus anti-CTLA4 inhibitor Infusion | First-line treatment for intermediate and poor risk advanced RCC | Available on the NHS |

| | | | | |
|--|---|--|---|---|
| Sutent <i>Pfizer</i> | Sunitinib | Targeted therapy: VEGF tyrosine kinase inhibitor (TKI) Oral medication | First-line treatment for metastatic RCC | Available on the NHS |
| Votrient <i>Novartis</i> | Pazopanib | Targeted therapy: VEGF tyrosine kinase inhibitor (TKI) Oral medication | First-line treatment for metastatic RCC | Available on the NHS |
| Cabometyx <i>Ipsen</i> | Cabozantinib | Targeted therapy: VEGF tyrosine kinase inhibitor (TKI) Oral medication | First-line treatment for locally advanced/metastatic RCC | Available on the NHS |
| Fotivda <i>Aveo/Eusa</i> | Tivozanib | Targeted therapy: VEGF tyrosine kinase inhibitor (TKI) Oral medication | First-line treatment for metastatic RCC | Available on the NHS |
| Second-line treatments | | | | |
| Kisplyx plus Afinitor <i>Eisai, Novartis</i> | Lenvatinib in combination with everolimus | Targeted therapy: VEGF tyrosine kinase inhibitor (TKI) plus mTOR inhibitor Oral medication | Second-line treatment for advanced RCC | Available on the NHS |
| Inlyta <i>Pfizer</i> | Axitinib | Targeted therapy: VEGF tyrosine kinase inhibitor (TKI) Oral medication | Second-line treatment for advanced RCC | Available on the NHS |
| Second line and beyond treatments | | | | |
| Opdivo <i>BMS</i> | Nivolumab | Immunotherapy: Anti-PD1 checkpoint inhibitor | Second/third-line treatment for advanced/metastatic RCC | Available on the NHS |
| Cabometyx <i>Ipsen</i> | Cabozantinib | Targeted therapy: VEGF tyrosine kinase inhibitor (TKI) Oral medication | Second/third-line treatment for advanced RCC after VEGF-TKI treatment | Available on the NHS |
| Afinitor <i>Novartis</i> | Everolimus | Targeted therapy: mTOR inhibitor Oral medication | Second/third-line treatment for advanced RCC | Available on the NHS in England, Scotland and Wales |

| Other treatments for advanced kidney cancer | | | | |
|--|--|---|---|---|
| Proleukin <i>Clinigen</i> | Interleukin 2 (IL 2) | Immunotherapy: Cytokine Infusion | Advanced/metastatic RCC | Available to pre-selected patients only at specialist research sites (Christie Hospital, Manchester). Not funded by the NHS |
| Torisel <i>Pfizer</i> | Temsirolimus | Targeted therapy: mTOR inhibitor Oral medication | First-line treatment for advanced RCC of poor prognosis | Not routinely available on the NHS Access via individual funding request* |
| Avastin <i>Roche</i> | Bevacizumab | Targeted therapy: VEGF tyrosine kinase inhibitor (TKI) Infusion | First-line treatment for advanced/metastatic RCC in combination with interferon alpha | Not routinely available on the NHS Access via individual funding request* |
| Nexavar <i>Bayer</i> | Sorafenib | Targeted therapy: VEGF tyrosine kinase inhibitor (TKI) Oral medication | First/second-line treatment for advanced/metastatic RCC | Not routinely available on the NHS Access via individual funding request* |
| Tecentriq plus Avastin <i>Roche</i> | Atezolizumab in combination with bevacizumab | Immunotherapy plus targeted therapy: Anti-PD-L1 checkpoint inhibitor plus VEGF tyrosine kinase inhibitor (TKI) Infusion | First-line treatment for locally advanced/metastatic RCC | Appraisal suspended |
| Xgeva <i>Amgen</i> | Denosumab | Immunotherapy: RANK ligand inhibitor Injection | Cancer that has spread to the bones as an alternative to bisphosphonates | Available on the NHS |

Clinical Trials for Kidney Cancer - Please go to our [clinical trials database](#) for a complete list of all clinical trials for kidney cancer in the UK:

*Individual funding requests may be submitted via the following route:

- England and Northern Ireland: [Individual Funding Request \(IFR\)](#)
- Wales: [Individual Patient Funding Request \(IPFR\)](#)
- Scotland: [Individual Patient Treatment Request \(IPTR\)](#)